XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Cash Flows From Operating Activities:        
Net loss $ (4,361,000) $ (7,726,000) $ (21,743,000) $ (21,206,000)
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock-based compensation     501,000 509,000
In-process research and development impairment 0 1,325,000   1,325,000
Goodwill impairment   1,526,000   5,594,000
Change in fair value of contingent consideration     9,806,000 514,000
Non-cash lease expense     383,000 335,000
Depreciation     81,000 110,000
Deferred research and development tax credit     (1,306,000) (669,000)
Changes in operating assets and liabilities:        
Prepaid expenses and other current assets     866,000 1,124,000
Accounts payable     (140,000) (21,000)
Accrued expenses     (1,386,000) 725,000
Accrued employee benefits     (436,000) (229,000)
Operating lease liability     (413,000) (357,000)
Net Cash Used In Operating Activities     (13,787,000) (12,246,000)
Cash Flows from Investing Activities        
Purchase of property and equipment     (35,000) (1,000)
Net Cash Used in Investing Activities     (35,000) (1,000)
Cash Flows from Financing Activities        
Tax credit receivable     1,839,000  
Proceeds from issuance of common stock     6,690,000 1,953,000
Proceeds from issuance of common stock for warrant exercises     4,000  
Payment of loans payable     (69,000) (67,000)
Proceeds from issuance ATM offering, net of issuance costs     279,000 3,603,000
Payment of contingent consideration     (500,000)  
Proceeds from long term debt     1,492,000  
Net Cash provided by Financing Activities     9,735,000 5,489,000
Effects of exchange rate changes on cash and cash equivalents     (44,000) (9,000)
Net increase (decrease) in cash and cash equivalents and restricted cash     (4,131,000) (6,767,000)
Cash, cash equivalents and restricted cash at the beginning of this period     11,705,000 23,279,000
Cash, cash equivalents and restricted cash at the end of this period 7,574,000 16,512,000 7,574,000 16,512,000
Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet        
Cash and cash equivalents 7,528,000 16,409,000 7,528,000 16,409,000
Restricted cash included in other long-term assets 46,000 103,000 46,000 103,000
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 7,574,000 $ 16,512,000 $ 7,574,000 $ 16,512,000